[go: up one dir, main page]

NO20043115L - Substituerte diketopiperaziner som oksytocin antagonister - Google Patents

Substituerte diketopiperaziner som oksytocin antagonister

Info

Publication number
NO20043115L
NO20043115L NO20043115A NO20043115A NO20043115L NO 20043115 L NO20043115 L NO 20043115L NO 20043115 A NO20043115 A NO 20043115A NO 20043115 A NO20043115 A NO 20043115A NO 20043115 L NO20043115 L NO 20043115L
Authority
NO
Norway
Prior art keywords
oxytocin antagonists
substituted diketopiperazines
oxytocin
diketopiperazines
substituted
Prior art date
Application number
NO20043115A
Other languages
English (en)
Other versions
NO329543B1 (no
Inventor
Andrew Mcmurtrie Mason
Deirdre Mary Bernadette Hickey
John Liddle
Alan David Borthwick
Richard Jonathan Hatley
David George Hubert Livermore
Neil Derek Miller
Fabrizio Nerozzi
Steven Leslie Sollis
Anna Katrin Szardenings
Paul Graham Wyatt
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NO20043115L publication Critical patent/NO20043115L/no
Publication of NO329543B1 publication Critical patent/NO329543B1/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06Antiabortive agents; Labour repressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06078Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06191Dipeptides containing heteroatoms different from O, S, or N
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20043115A 2001-12-21 2004-07-20 Diketopiperazinderivater, farmasoytiske sammensetninger samt anvendelser derav NO329543B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0130677.8A GB0130677D0 (en) 2001-12-21 2001-12-21 Medicaments and novel compounds
PCT/EP2002/014823 WO2003053443A1 (en) 2001-12-21 2002-12-20 Substituted diketopiperazines as oxytocin antagonists

Publications (2)

Publication Number Publication Date
NO20043115L true NO20043115L (no) 2004-07-20
NO329543B1 NO329543B1 (no) 2010-11-08

Family

ID=9928187

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20043115A NO329543B1 (no) 2001-12-21 2004-07-20 Diketopiperazinderivater, farmasoytiske sammensetninger samt anvendelser derav

Country Status (27)

Country Link
US (3) US7514437B2 (no)
EP (1) EP1458393B1 (no)
JP (1) JP4638149B2 (no)
KR (2) KR100997856B1 (no)
CN (1) CN100374115C (no)
AT (1) ATE399011T1 (no)
AU (1) AU2002364304B2 (no)
BR (1) BRPI0215277B1 (no)
CA (1) CA2471355C (no)
CO (1) CO5590916A2 (no)
CY (1) CY1108334T1 (no)
DE (1) DE60227283D1 (no)
DK (1) DK1458393T3 (no)
ES (1) ES2307827T3 (no)
GB (1) GB0130677D0 (no)
HU (1) HU229708B1 (no)
IL (2) IL162515A0 (no)
IS (1) IS2613B (no)
MX (1) MXPA04006033A (no)
NO (1) NO329543B1 (no)
NZ (1) NZ533218A (no)
PL (1) PL215826B1 (no)
PT (1) PT1458393E (no)
RU (1) RU2303032C2 (no)
SI (1) SI1458393T1 (no)
WO (1) WO2003053443A1 (no)
ZA (1) ZA200404326B (no)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0314738D0 (en) 2003-06-24 2003-07-30 Glaxo Group Ltd Novel compounds
GB0314733D0 (en) * 2003-06-24 2003-07-30 Glaxo Group Ltd Medicaments
GB0414100D0 (en) * 2004-06-23 2004-07-28 Glaxo Group Ltd Novel compounds
GB0414093D0 (en) * 2004-06-23 2004-07-28 Glaxo Group Ltd Novel compounds
GB0414092D0 (en) * 2004-06-23 2004-07-28 Glaxo Group Ltd Novel compounds
GB0428235D0 (en) * 2004-12-23 2005-01-26 Glaxo Group Ltd Novel compounds
AP2007004047A0 (en) 2005-01-20 2007-06-30 Pfizer Ltd Substituted triazole derivatives as oxtocin antagonists
RU2318818C1 (ru) * 2006-04-12 2008-03-10 Общество С Ограниченной Ответственностью "Исследовательский Институт Химического Разнообразия" Азагетероциклы, комбинаторная библиотека, фокусированная библиотека, фармацевтическая композиция и способ получения (варианты)
WO2009105774A2 (en) 2008-02-21 2009-08-27 Sequoia Pharmaceuticals, Inc. Amino acid inhibitors of cytochrome p450
AU2009284668B2 (en) * 2008-08-22 2015-07-09 British Columbia Cancer Agency Branch Small molecule inhibitors of N-terminus activation of the androgen receptor
WO2011051814A1 (en) 2009-10-30 2011-05-05 Glaxo Group Limited Novel crystalline forms of (3r,6r) -3- (2, 3 -dihydro- 1h- inden- 2 -yl) - 1 - [ (1r) - 1 - (2, 6 - dimethyl - 3 - pyridinyl) - 2 - (4 -morpholinyl) -2-oxoethyl] -6- [(1s) - 1 -methylpropyl] -2,5- piperazinedione
WO2012055509A1 (en) * 2010-10-29 2012-05-03 Lonza Ltd Diketopiperazine forming dipeptidyl linker
CN103242246A (zh) * 2013-05-21 2013-08-14 苏州科捷生物医药有限公司 3-位取代的n-甲基哌嗪的合成方法
CN105061317B (zh) * 2015-08-26 2017-08-25 浙江大果生物医药科技有限公司 一类吲唑盐类化合物及其制备方法和应用
SG11201804789QA (en) 2016-01-04 2018-07-30 ObsEva SA Alpha-amino esters of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof
SG11201900461UA (en) 2016-07-21 2019-02-27 ObsEva SA Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage
CN109305969B (zh) * 2017-07-27 2023-03-10 江苏恒瑞医药股份有限公司 哌嗪-2,5-二酮类衍生物、其制备方法及其在医药上的应用
CN109485598A (zh) * 2018-11-29 2019-03-19 河南师范大学 一种去除氨基上喹啉保护基的新方法
WO2021043726A1 (en) 2019-09-03 2021-03-11 ObsEva S.A. Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage
CN115380122A (zh) 2020-02-10 2022-11-22 奥布赛瓦股份公司 用于催产素受体拮抗剂疗法的生物标志物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4596819A (en) * 1984-01-23 1986-06-24 Warner-Lambert Company Modified tripeptides
HUT67287A (en) * 1991-09-13 1995-03-28 Merck & Co Inc Piperazynil camphor derivatives and pharmaceutical compositions containing them
US5464788A (en) * 1994-03-24 1995-11-07 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
US5817751A (en) * 1994-06-23 1998-10-06 Affymax Technologies N.V. Method for synthesis of diketopiperazine and diketomorpholine derivatives
GB2326639A (en) * 1997-06-18 1998-12-30 Merck & Co Inc Piperazine Oxytocin Receptor Antagonists
GB9713748D0 (en) * 1997-06-27 1997-09-03 Unilever Plc Production of detergent granulates
AU745425B2 (en) * 1998-01-27 2002-03-21 Aventis Pharmaceuticals Inc. Substituted oxoazaheterocyclyl factor Xa inhibitors
KR20010034469A (ko) 1998-01-29 2001-04-25 아벤티스 파마슈티칼즈 프로덕츠 인코포레이티드 N-[(지방족 또는 방향족)카보닐]-2-아미노아세트아미드화합물 및 환화 화합물의 제조방법
US6107274A (en) * 1998-03-16 2000-08-22 Ontogen Corporation Piperazines as inhibitors of fructose-1,6-bisphosphatase (FBPase)
GB0314738D0 (en) 2003-06-24 2003-07-30 Glaxo Group Ltd Novel compounds
GB0314733D0 (en) 2003-06-24 2003-07-30 Glaxo Group Ltd Medicaments
GB0414092D0 (en) 2004-06-23 2004-07-28 Glaxo Group Ltd Novel compounds
GB0414093D0 (en) 2004-06-23 2004-07-28 Glaxo Group Ltd Novel compounds
GB0414100D0 (en) 2004-06-23 2004-07-28 Glaxo Group Ltd Novel compounds
GB0428235D0 (en) 2004-12-23 2005-01-26 Glaxo Group Ltd Novel compounds

Also Published As

Publication number Publication date
EP1458393B1 (en) 2008-06-25
GB0130677D0 (en) 2002-02-06
AU2002364304A1 (en) 2003-07-09
CA2471355A1 (en) 2003-07-03
ATE399011T1 (de) 2008-07-15
IL162515A (en) 2012-08-30
PL370981A1 (en) 2005-06-13
HUP0500136A2 (hu) 2005-05-30
IS7315A (is) 2004-06-16
HK1069339A1 (en) 2005-05-20
KR20040065285A (ko) 2004-07-21
KR20100060012A (ko) 2010-06-04
NO329543B1 (no) 2010-11-08
US7514437B2 (en) 2009-04-07
CN1606443A (zh) 2005-04-13
JP4638149B2 (ja) 2011-02-23
PT1458393E (pt) 2008-09-29
IS2613B (is) 2010-04-15
US20050148572A1 (en) 2005-07-07
US8367673B2 (en) 2013-02-05
CN100374115C (zh) 2008-03-12
PL215826B1 (pl) 2014-01-31
BRPI0215277B1 (pt) 2016-05-03
CO5590916A2 (es) 2005-12-30
NZ533218A (en) 2007-01-26
HU229708B1 (en) 2014-05-28
ES2307827T3 (es) 2008-12-01
DE60227283D1 (de) 2008-08-07
MXPA04006033A (es) 2004-09-27
JP2005517663A (ja) 2005-06-16
RU2004122392A (ru) 2005-04-20
CA2471355C (en) 2013-04-23
DK1458393T3 (da) 2008-10-13
SI1458393T1 (sl) 2008-10-31
KR100997856B1 (ko) 2010-12-01
US8541579B2 (en) 2013-09-24
EP1458393A1 (en) 2004-09-22
BR0215277A (pt) 2004-12-14
US20090186867A1 (en) 2009-07-23
CY1108334T1 (el) 2014-02-12
IL162515A0 (en) 2005-11-20
RU2303032C2 (ru) 2007-07-20
US20130131338A1 (en) 2013-05-23
AU2002364304B2 (en) 2008-04-17
WO2003053443A1 (en) 2003-07-03
ZA200404326B (en) 2005-09-28

Similar Documents

Publication Publication Date Title
DK1458393T3 (da) Substituerede diketopiperaziner som oxytocinantagonister
CY1107853T1 (el) Χρησεις αντισπασμωδικων αμινοξεων για τη θεραπευτικη αγωγη διπολικων διαταραχων
EA200300776A1 (ru) Производные фенэтаноламина для лечения респираторных заболеваний
HRP20090281T1 (hr) 1,2,3,4-tetrasubstituirani indol za liječenje respiratornih bolesti
CY1109242T1 (el) Θεραπευτικοι παραγοντες χρησιμοι για θεραπεια πονου
EA200100971A1 (ru) Новые соединения и композиции в качестве ингибиторов протеазы
ATE440603T1 (de) 8-hydroxychinolinderivate
ATE371656T1 (de) Heteroaryl-pyrimidinderivate als jak-inhibitoren
IS8502A (is) Azatvíhringja heteróhringir sem kannabínóíð-viðtakastillar
BG66085B1 (bg) Фенилаланинови производни
CY1111396T1 (el) Ρινικη χορηγηση μετοκλοπραμιδης για την αγωγη της γαστροπαρεσης
TNSN04203A1 (en) Benzoxazinone-derived compounds, their preparation and use as medicaments
BR0108816A (pt) Derivados de quinolina como antagonistas alfa-2
PE20030061A1 (es) 1-biaril-1,8-naftiridin-4-ona como inhibidores de fosfodiesterasa-4
EA200301203A1 (ru) Новые соединения и композиции как ингибиторы катепсина
SE9902267D0 (sv) New compounds
AU2001246999A1 (en) New neurokinin antagonists for use as medicaments
EA200201232A1 (ru) Производные сульфонамида
SE0004827D0 (sv) Therapeutic compounds
AU2001244999A1 (en) Naphthamide neurokinin antagonists for use as medicaments
CY1106385T1 (el) Χρηση παραγωγων της εποθειλονης για τη θepαπεια του υπepπαραθυρεοειδισμου
EA200401432A1 (ru) Сложноэфирные производные декагидроизохинолин-3-карбоновой кислоты в качестве анальгетиков
SE0100873D0 (sv) Method of treatment
WO2005035500A3 (en) Therapeutic agents useful for treating pain
AU2002211217A1 (en) Method of treating stroke

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: GLAXO GROUP LTD, GB

MM1K Lapsed by not paying the annual fees